HDAC6 and breast cancer: In the present study, poloxamer L‐61 modified polylactic acid block copolymers were synthesized to prepare isoform‐specific single agent PI3‐Kδ/HDAC6 dual inhibitor (Figure S1) encapsulated nanoformulation (HSB‐510) to treat breast cancer.